DDInter1055 DDInter1024
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Levofloxacin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Lapatinib
Levofloxacin {u} (Compound) downregulates {v} (Gene) SUPV3L1
SUPV3L1 {u} (Gene) is downregulated by {v} (Compound) Lapatinib
Levofloxacin {u} (Compound) causes {v} (Side Effect) Infestation NOS
Infestation NOS {u} (Side Effect) is caused by {v} (Compound) Lapatinib
Levofloxacin {u} (Compound) resembles {v} (Compound) Lomefloxacin
Lomefloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may lead to a major life threatening interaction when taken with {v} Lapatinib
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may lead to a major life threatening interaction when taken with {v} Lapatinib
Levofloxacin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is associated with {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Lapatinib
Levofloxacin {u} (Compound) downregulates {v} (Gene) SUPV3L1
SUPV3L1 {u} (Gene) is regulated by {v} (Gene) VAV3
VAV3 {u} (Gene) is upregulated by {v} (Compound) Lapatinib
Levofloxacin {u} (Compound) downregulates {v} (Gene) PTPN1
PTPN1 {u} (Gene) interacts with {v} (Gene) EGFR
EGFR {u} (Gene) is bound by {v} (Compound) Lapatinib
Levofloxacin {u} (Compound) downregulates {v} (Gene) SDC1
SDC1 {u} (Gene) is upregulated by {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Lapatinib
Levofloxacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Levofloxacin (Compound) downregulates SUPV3L1 (Gene) and SUPV3L1 (Gene) is downregulated by Lapatinib (Compound)
Levofloxacin (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Lapatinib (Compound)
Levofloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may lead to a major life threatening interaction when taken with Lapatinib
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may lead to a major life threatening interaction when taken with Lapatinib
Levofloxacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is associated with breast cancer (Disease) and breast cancer (Disease) is treated by Lapatinib (Compound)
Levofloxacin (Compound) downregulates SUPV3L1 (Gene) and SUPV3L1 (Gene) is regulated by VAV3 (Gene) and VAV3 (Gene) is upregulated by Lapatinib (Compound)
Levofloxacin (Compound) downregulates PTPN1 (Gene) and PTPN1 (Gene) interacts with EGFR (Gene) and EGFR (Gene) is bound by Lapatinib (Compound)
Levofloxacin (Compound) downregulates SDC1 (Gene) and SDC1 (Gene) is upregulated by breast cancer (Disease) and breast cancer (Disease) is treated by Lapatinib (Compound)